Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is conducting a Phase 2, open-label, multicenter study titled ...

Ianalumab added to eltrombopag significantly prolonged the time to treatment failure (TTF) in adults with primary immune thrombocytopenia (ITP), a B cell-driven autoimmune disease, according to phase ...

Thrombotic thrombocytopenic purpura (TTP) is an extremely rare thrombotic microangiopathy characterized by ADAMTS-13 deficiency. Deficiency of ADAMTS-13, a cleaving protease of von Willebrand Factor ...

Novartis' ianalumab plus eltrombopag significantly extended treatment response and improved platelet counts in a Phase 3 ...

Novartis (NVS) announced positive top-line results from VAYHIT2, a Phase III trial evaluating ianalumab plus eltrombopag in patients with primary ...

Ianalumab prolonged the duration of safe platelet levels during and after treatment in patients with primary immune thrombocytopenia (ITP) previously treated with corticosteroids1,2 Patients treated ...

An expert discusses the importance of patient education and personalized, flexible treatment planning in managing chronic ...

An expert discusses treatment strategies for immune thrombocytopenic purpura (ITP), emphasizing individualized decisions ...

Kuwana M, Okazaki Y, and Ikeda Y. Splenic macrophages maintain the anti-platelet autoimmune response via uptake of opsonized platelets in patients with immune thrombocytopenic purpura.

Seeing sick-looking faces in virtual reality triggers brain circuit changes related to threat detection and boosts activity of certain immune cells.

Sobi Announces U.S. Food and Drug Administration Approves Doptelet® (avatrombopag) for the Treatment of Thrombocytopenia in Pediatric Patients One Year and Older with Persistent or Chronic Immune ...